EUVIMEDSkopri EUVIMED
Crossref

FDA approves drug to treat neurologic manifestations of Hunter syndrome

The Brown University Child & Adolescent Psychopharmacology Update · 2026-05 · 28 (5) · 8-8

DOI: 10.1002/cpu.31062 ↗

At a glance

Journal article in The Brown University Child & Adolescent Psychopharmacology Update, published online on 2026-04-27.

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

The U.S. Food and Drug Administration approved Avlayah to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).

Cite

APA

(2026). FDA approves drug to treat neurologic manifestations of Hunter syndrome. The Brown University Child & Adolescent Psychopharmacology Update, 28(5), 8-8. https://doi.org/10.1002/cpu.31062

Vancouver

FDA approves drug to treat neurologic manifestations of Hunter syndrome. The Brown University Child & Adolescent Psychopharmacology Update. 2026;28(5):8-8. doi:10.1002/cpu.31062

BibTeX
@article{euvimed2026,
  title = {FDA approves drug to treat neurologic manifestations of Hunter syndrome},
  journal = {The Brown University Child & Adolescent Psychopharmacology Update},
  year = {2026},
  volume = {28},
  number = {5},
  pages = {8--8},
  doi = {10.1002/cpu.31062}
}
Start for free →